A multicenter randomized controlled trial to evaluate the efficacy and safety of nelfinavir in patients with mild COVID-19
Nelfinavir, an orally administered inhibitor of human immunodeficiency virus protease, inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) <i>in vitro</i>. We conducted a randomized controlled trial to evaluate the clinical efficacy and safety of nelf...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Society for Microbiology
2023
|
| _version_ | 1811139179070881792 |
|---|---|
| author | Miyazaki, T Hosogaya, N Fukushige, Y Takemori, S Morimoto, S Yamamoto, H Hori, M Ozawa, Y Shiko, Y Inaba, Y Kurokawa, T Hanaoka, H Iwanami, S Kim, K Iwami, S Watashi, K Miyazawa, K Umeyama, T Yamagoe, S Miyazaki, Y Wakita, T Sumiyoshi, M Hirayama, T Izumikawa, K Yanagihara, K Mukae, H Kawasuji, H Yamamoto, Y Tarumoto, N Ishii, H Ohno, H Yatera, K Kakeya, H Kichikawa, Y Kato, Y Matsumoto, T Saito, M Yotsuyanagi, H Kohno, S |
| author_facet | Miyazaki, T Hosogaya, N Fukushige, Y Takemori, S Morimoto, S Yamamoto, H Hori, M Ozawa, Y Shiko, Y Inaba, Y Kurokawa, T Hanaoka, H Iwanami, S Kim, K Iwami, S Watashi, K Miyazawa, K Umeyama, T Yamagoe, S Miyazaki, Y Wakita, T Sumiyoshi, M Hirayama, T Izumikawa, K Yanagihara, K Mukae, H Kawasuji, H Yamamoto, Y Tarumoto, N Ishii, H Ohno, H Yatera, K Kakeya, H Kichikawa, Y Kato, Y Matsumoto, T Saito, M Yotsuyanagi, H Kohno, S |
| author_sort | Miyazaki, T |
| collection | OXFORD |
| description | Nelfinavir, an orally administered inhibitor of human immunodeficiency virus protease, inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) <i>in vitro</i>. We conducted a randomized controlled trial to evaluate the clinical efficacy and safety of nelfinavir in patients with SARS-CoV-2 infection. We included unvaccinated asymptomatic or mildly symptomatic adult patients who tested positive for SARS-CoV-2 infection within 3 days before enrollment. The patients were randomly assigned (1:1) to receive oral nelfinavir (750 mg; thrice daily for 14 days) combined with standard-of-care or standard-of-care alone. The primary endpoint was the time to viral clearance, confirmed using quantitative reverse-transcription PCR by assessors blinded to the assigned treatment. A total of 123 patients (63 in the nelfinavir group and 60 in the control group) were included. The median time to viral clearance was 8.0 (95% confidence interval [CI], 7.0 to 12.0) days in the nelfinavir group and 8.0 (95% CI, 7.0 to 10.0) days in the control group, with no significant difference between the treatment groups (hazard ratio, 0.815; 95% CI, 0.563 to 1.182; <i>P </i>= 0.1870). Adverse events were reported in 47 (74.6%) and 20 (33.3%) patients in the nelfinavir and control groups, respectively. The most common adverse event in the nelfinavir group was diarrhea (49.2%). Nelfinavir did not reduce the time to viral clearance in this setting. Our findings indicate that nelfinavir should not be recommended in asymptomatic or mildly symptomatic patients infected with SARS-CoV-2. The study is registered with the Japan Registry of Clinical Trials (jRCT2071200023). <br><br><b>IMPORTANCE</b> The anti-HIV drug nelfinavir suppresses the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) <i>in vitro</i>. However, its efficacy in patients with COVID-19 has not been studied. We conducted a multicenter, randomized controlled trial to evaluate the efficacy and safety of orally administered nelfinavir in patients with asymptomatic or mildly symptomatic COVID-19. Compared to standard-of-care alone, nelfinavir (750 mg, thrice daily) did not reduce the time to viral clearance, viral load, or the time to resolution of symptoms. More patients had adverse events in the nelfinavir group than in the control group (74.6% [47/63 patients] versus 33.3% [20/60 patients]). Our clinical study provides evidence that nelfinavir, despite its antiviral effects on SARS-CoV-2 <i>in vitro</i>, should not be recommended for the treatment of patients with COVID-19 having no or mild symptoms. |
| first_indexed | 2024-09-25T04:01:58Z |
| format | Journal article |
| id | oxford-uuid:8de45492-d7e8-4e9d-a750-af285d765c6e |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-09-25T04:01:58Z |
| publishDate | 2023 |
| publisher | American Society for Microbiology |
| record_format | dspace |
| spelling | oxford-uuid:8de45492-d7e8-4e9d-a750-af285d765c6e2024-04-29T16:30:28ZA multicenter randomized controlled trial to evaluate the efficacy and safety of nelfinavir in patients with mild COVID-19Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8de45492-d7e8-4e9d-a750-af285d765c6eEnglishSymplectic ElementsAmerican Society for Microbiology2023Miyazaki, THosogaya, NFukushige, YTakemori, SMorimoto, SYamamoto, HHori, MOzawa, YShiko, YInaba, YKurokawa, THanaoka, HIwanami, SKim, KIwami, SWatashi, KMiyazawa, KUmeyama, TYamagoe, SMiyazaki, YWakita, TSumiyoshi, MHirayama, TIzumikawa, KYanagihara, KMukae, HKawasuji, HYamamoto, YTarumoto, NIshii, HOhno, HYatera, KKakeya, HKichikawa, YKato, YMatsumoto, TSaito, MYotsuyanagi, HKohno, SNelfinavir, an orally administered inhibitor of human immunodeficiency virus protease, inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) <i>in vitro</i>. We conducted a randomized controlled trial to evaluate the clinical efficacy and safety of nelfinavir in patients with SARS-CoV-2 infection. We included unvaccinated asymptomatic or mildly symptomatic adult patients who tested positive for SARS-CoV-2 infection within 3 days before enrollment. The patients were randomly assigned (1:1) to receive oral nelfinavir (750 mg; thrice daily for 14 days) combined with standard-of-care or standard-of-care alone. The primary endpoint was the time to viral clearance, confirmed using quantitative reverse-transcription PCR by assessors blinded to the assigned treatment. A total of 123 patients (63 in the nelfinavir group and 60 in the control group) were included. The median time to viral clearance was 8.0 (95% confidence interval [CI], 7.0 to 12.0) days in the nelfinavir group and 8.0 (95% CI, 7.0 to 10.0) days in the control group, with no significant difference between the treatment groups (hazard ratio, 0.815; 95% CI, 0.563 to 1.182; <i>P </i>= 0.1870). Adverse events were reported in 47 (74.6%) and 20 (33.3%) patients in the nelfinavir and control groups, respectively. The most common adverse event in the nelfinavir group was diarrhea (49.2%). Nelfinavir did not reduce the time to viral clearance in this setting. Our findings indicate that nelfinavir should not be recommended in asymptomatic or mildly symptomatic patients infected with SARS-CoV-2. The study is registered with the Japan Registry of Clinical Trials (jRCT2071200023). <br><br><b>IMPORTANCE</b> The anti-HIV drug nelfinavir suppresses the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) <i>in vitro</i>. However, its efficacy in patients with COVID-19 has not been studied. We conducted a multicenter, randomized controlled trial to evaluate the efficacy and safety of orally administered nelfinavir in patients with asymptomatic or mildly symptomatic COVID-19. Compared to standard-of-care alone, nelfinavir (750 mg, thrice daily) did not reduce the time to viral clearance, viral load, or the time to resolution of symptoms. More patients had adverse events in the nelfinavir group than in the control group (74.6% [47/63 patients] versus 33.3% [20/60 patients]). Our clinical study provides evidence that nelfinavir, despite its antiviral effects on SARS-CoV-2 <i>in vitro</i>, should not be recommended for the treatment of patients with COVID-19 having no or mild symptoms. |
| spellingShingle | Miyazaki, T Hosogaya, N Fukushige, Y Takemori, S Morimoto, S Yamamoto, H Hori, M Ozawa, Y Shiko, Y Inaba, Y Kurokawa, T Hanaoka, H Iwanami, S Kim, K Iwami, S Watashi, K Miyazawa, K Umeyama, T Yamagoe, S Miyazaki, Y Wakita, T Sumiyoshi, M Hirayama, T Izumikawa, K Yanagihara, K Mukae, H Kawasuji, H Yamamoto, Y Tarumoto, N Ishii, H Ohno, H Yatera, K Kakeya, H Kichikawa, Y Kato, Y Matsumoto, T Saito, M Yotsuyanagi, H Kohno, S A multicenter randomized controlled trial to evaluate the efficacy and safety of nelfinavir in patients with mild COVID-19 |
| title | A multicenter randomized controlled trial to evaluate the efficacy and safety of nelfinavir in patients with mild COVID-19 |
| title_full | A multicenter randomized controlled trial to evaluate the efficacy and safety of nelfinavir in patients with mild COVID-19 |
| title_fullStr | A multicenter randomized controlled trial to evaluate the efficacy and safety of nelfinavir in patients with mild COVID-19 |
| title_full_unstemmed | A multicenter randomized controlled trial to evaluate the efficacy and safety of nelfinavir in patients with mild COVID-19 |
| title_short | A multicenter randomized controlled trial to evaluate the efficacy and safety of nelfinavir in patients with mild COVID-19 |
| title_sort | multicenter randomized controlled trial to evaluate the efficacy and safety of nelfinavir in patients with mild covid 19 |
| work_keys_str_mv | AT miyazakit amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT hosogayan amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT fukushigey amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT takemoris amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT morimotos amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT yamamotoh amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT horim amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT ozaway amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT shikoy amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT inabay amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT kurokawat amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT hanaokah amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT iwanamis amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT kimk amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT iwamis amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT watashik amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT miyazawak amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT umeyamat amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT yamagoes amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT miyazakiy amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT wakitat amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT sumiyoshim amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT hirayamat amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT izumikawak amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT yanagiharak amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT mukaeh amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT kawasujih amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT yamamotoy amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT tarumoton amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT ishiih amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT ohnoh amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT yaterak amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT kakeyah amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT kichikaway amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT katoy amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT matsumotot amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT saitom amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT yotsuyanagih amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT kohnos amulticenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT miyazakit multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT hosogayan multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT fukushigey multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT takemoris multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT morimotos multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT yamamotoh multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT horim multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT ozaway multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT shikoy multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT inabay multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT kurokawat multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT hanaokah multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT iwanamis multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT kimk multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT iwamis multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT watashik multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT miyazawak multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT umeyamat multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT yamagoes multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT miyazakiy multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT wakitat multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT sumiyoshim multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT hirayamat multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT izumikawak multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT yanagiharak multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT mukaeh multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT kawasujih multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT yamamotoy multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT tarumoton multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT ishiih multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT ohnoh multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT yaterak multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT kakeyah multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT kichikaway multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT katoy multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT matsumotot multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT saitom multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT yotsuyanagih multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 AT kohnos multicenterrandomizedcontrolledtrialtoevaluatetheefficacyandsafetyofnelfinavirinpatientswithmildcovid19 |